Literature DB >> 23162533

Role of vitamin D on cancer immunotherapy.

Ashraf Karbasi1, Amin Saburi.   

Abstract

Entities:  

Year:  2012        PMID: 23162533      PMCID: PMC3499768          DOI: 10.3389/fendo.2012.00132

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


× No keyword cloud information.
Dear Editor in Chief, With a great interest, we read a recently published paper in Frontier in Endocrinology journal by Vuolo et al., entitled “Vitamin D and Cancer” (Vuolo et al., 2012). They skillfully reviewed the role of vitamin D in all aspects of cancer such as cancer prevention, immune system and cancer, reverse effect of cancer on vitamin D, and vitamin D status in some important type of malignancy. This issue is a hot topic in oncology, but in this study there are some concerns which undermine the results to make a definite conclusion. Although they concluded that “The immune system seems to represent a relevant target for the antineoplastic effects of vitamin D,” (Vuolo et al., 2012) they did not consider anti-neoplastic role of activated form of vitamin D using for immunotherapy of cancer. It was recently shown that a group of vitamin D-binding protein (DBP) so called Gc protein is an important precursor for activating macrophage as one of the main innate immune cell for cancer immunotherapy (Nagasawa et al., 2005). Although the aim of the review by Vuolo et al. was the role of Vitamin D in cancer, it was confirmed that the level of vitamin D is related to Vitamin D binding proteins (Carpenter et al., 2012). In normal tissue, when a neoplastic tissue is arise, DBP is naturally activated by glycosylation and transform to DBP-derived macrophage-activating factor (Gc-MAF) by b-galactosidase and sialidase of B and T cells, respectively, which can activate macrophage to phagocyte the neoplastic cells. Group-specific component protein (Gc) as DBP preserve vitamin D in body fluids and put it available for tissues. But an enzyme (a-N-acetylgalactosaminidase) produced by neoplastic cells deactivate and denaturize this factor and provide neoplastic cells to spread (Yamamoto and Naraparaju, 1998; Ghanei et al., 2012). In some clinical studies, Gc-MAF has successfully been used for prostate, colorectal, and breast cancer (Yamamoto and Suyama, 2008; Yamamoto et al., 2008a,b). Therefore, vitamin D has a prominent role in natural tumorocidal activity of immune system as an initial precursor.
  8 in total

1.  The new aspects of immunotherapy in prostate cancer.

Authors:  Mostafa Ghanei; Majid Shohrati; Amin Saburi
Journal:  Cancer Immunol Immunother       Date:  2012-06-27       Impact factor: 6.968

Review 2.  Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.

Authors:  Hideko Nagasawa; Yoshihiro Uto; Hideyuki Sasaki; Natsuko Okamura; Aya Murakami; Shinichi Kubo; Kenneth L Kirk; Hitoshi Hori
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

3.  Vitamin D binding protein is a key determinant of 25-hydroxyvitamin D levels in infants and toddlers.

Authors:  Thomas O Carpenter; Jane H Zhang; Esteban Parra; Bruce K Ellis; Christine Simpson; William M Lee; Jody Balko; Lei Fu; Betty Y-L Wong; David E C Cole
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

4.  Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.

Authors:  N Yamamoto; V R Naraparaju
Journal:  Immunol Cell Biol       Date:  1998-06       Impact factor: 5.126

5.  Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Nobuyuki Yamamoto
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

6.  Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Nobuyuki Yamamoto; Naofumi Ushijima
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

7.  Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Hiroaki Nakazato; Nobuyuki Yamamoto; Yoshihiko Koga
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

8.  Vitamin D and cancer.

Authors:  Laura Vuolo; Carolina Di Somma; Antongiulio Faggiano; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2012-04-23       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.